Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one of the worst performers on Wednesday. Moderna surged to a new 52-week high ...

The team applied this method to mRNA/saRNA constructs from 1 to 10 kb and assessed pH ranges from 3 to 6. For all the RNA constructs, the J2 immunoblot signal—a marker for dsRNA strands—decreased with ...